Top Markets
Coin of the day
Novartis AG Novartis AG

Novartis AG

NVS
株式のランク #47
Novartis AG researches, develops, manufactures, and markets healthcare products... Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
株価
$150.75
時価総額
$291.41B
変化(1日)
1.44%
変化(1年)
40.17%
CH
取引 Novartis AG (NVS)

カテゴリー

Novartis AG(NVS)の発行済株式数
March 2026 時点の発行済株式数 0
Novartis AG の最新の財務報告および株価によると、現在の発行済株式数は 0 です。March 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Novartis AG(NVS)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数
企業 発行済株式数
898.00M -
US
3.10B -
GB
2.43B -
US
1.78B -
US
2.49B -
US